Journal
CELL METABOLISM
Volume 32, Issue 1, Pages 44-+Publisher
CELL PRESS
DOI: 10.1016/j.cmet.2020.04.015
Keywords
-
Categories
Funding
- NCATS [R01DK108056, U01DE025383, UL1TR001998]
- University of Kentucky College of Medicine
- University of Kentucky Markey Cancer Center and Flow Cytometry Core [P30CA177558]
- Boston University Flow Cytometry Core Facility [T32AI089673]
- Boston University Medical Center, Metabolism, Endocrinology and Obesity training grant [T32DK007201]
- College of Health Sciences, Faculty Development grant (FDG), Merrimack College
- Sakowich Center for Undergraduate Research and Creative Activities grant (SCURCA), Merrimack College
Ask authors/readers for more resources
Age is a non-modifiable risk factor for the inflammation that underlies age-associated diseases; thus, anti-inflammaging drugs hold promise for increasing health span. Cytokine profiling and bioinformatic analyses showed that Th17 cytokine production differentiates CD4(+) T cells from lean, normoglycemic older and younger subjects, and mimics a diabetes-associated Th17 profile. T cells from older compared to younger subjects also had defects in autophagy and mitochondrial bioenergetics that associate with redox imbalance. Metformin ameliorated the Th17 inflammaging profile by increasing autophagy and improving mitochondrial bioenergetics. By contrast, autophagy-targeting siRNA disrupted redox balance in T cells from young subjects and activated the Th17 profile by activating the Th17 master regulator, STAT3, which in turn bound IL-17A and F promoters. Mitophagy-targeting siRNA failed to activate the Th17 profile. We conclude that metformin improves autophagy and mitochondrial function largely in parallel to ameliorate a newly defined inflammaging profile that echoes inflammation in diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available